Meg Tirrell joined CNBC in April 2014 as a general assignment reporter focusing on biotechnology and pharmaceuticals. She appears on CNBC's Business Day programming, contributes to CNBC.com and is based at the network's global headquarters in Englewood Cliffs, N.J.
Tirrell has covered development of new drugs for Alzheimer's, cancer and rare diseases, and tracked public health emergencies from Ebola to Zika. Her work has explored why fewer drugs are developed for children, chronicled the sequencing of her own genome, and followed the manufacturing of a flu shot from egg to pharmacy. In 2014, she revealed the agonizing decision-making behind Compassionate Use of unapproved drugs, and in 2016, she reported extensively on drug pricing controversies and the impact of politics on development of new medicines.
Prior to joining CNBC, Tirrell covered the biotechnology industry for Bloomberg News, where she also contributed to Bloomberg Television and Bloomberg Businessweek.
She holds a master's degree in journalism from Northwestern University and a bachelor's degree in English and music from Wellesley College.
Follow her on Twitter @megtirrell.
CNBC's Meg Tirrell reports on the quarterly earnings for Skechers.
CNBC's Meg Tirrell reports on Celgene stock halted on news the company will discontinue Crohn's disease drug trial.
CNBC's Meg Tirrell shares details of the FDA'a approval of Gilead's new immunotherapy drug to treat patients with non-Hodgkin lymphoma.
CNBC's Meg Tirrell reports on the FDA approving Gilead's cancer drug and what its priced at.
CNBC's Meg Tirrell reports on the latest patent lawsuits from the Saint Regis Mohawk Tribe.
The tribe is a co-plaintiff with SRC Labs, which claims its data processing technology patents have been infringed for years.
CNBC's Meg Tirrell reports on Johnson & Johnson's earnings beat and the verdict against the company on their talc product. She also reports on President Trump's tweet about Rep. Tom Marino (R-Pa.)
Dominic Caruso, Johnson & Johnson CFO breaks down the company's quarterly results and weighs in on whether he expects to see disruption in Puerto Rico manufacturing, and comments on drug pricing.
CNBC's Meg Tirrell reports on the latest developments on a federal court invalidating Allergan's eye drug patents.